RDD Pharma, Innovate Biopharmaceuticals and Naia Rare Diseases merged and formed 9 Meters Biopharma, which will develop treatments for orphan diseases and unmet needs in gastroenterology.
What you should know:
1. The merger also included a funding round that raised $22 million.
2. The company is advancing two therapies: larazotide, a therapy for celiac disease currently in a phase 3 trial, and GLP-1, which treats short bowel syndrome.
3. John Temperato will lead a management team that has brought a combined 15 drugs to market.